These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on selenite-treated rats. Wang S; Li D; Ito Y; Nabekura T; Wang S; Zhang J; Wu C Curr Eye Res; 2004 Jul; 29(1):51-8. PubMed ID: 15370367 [TBL] [Abstract][Full Text] [Related]
3. Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses. Gause S; Hsu KH; Shafor C; Dixon P; Powell KC; Chauhan A Adv Colloid Interface Sci; 2016 Jul; 233():139-154. PubMed ID: 26318359 [TBL] [Abstract][Full Text] [Related]
4. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies. Di Tommaso C; Bourges JL; Valamanesh F; Trubitsyn G; Torriglia A; Jeanny JC; Behar-Cohen F; Gurny R; Möller M Eur J Pharm Biopharm; 2012 Jun; 81(2):257-64. PubMed ID: 22445900 [TBL] [Abstract][Full Text] [Related]
5. Considerations in the use of hydroxypropyl-beta-cyclodextrin in the formulation of aqueous ophthalmic solutions of hydrocortisone. Bary AR; Tucker IG; Davies NM Eur J Pharm Biopharm; 2000 Sep; 50(2):237-44. PubMed ID: 10962233 [TBL] [Abstract][Full Text] [Related]
6. Application of Mechanistic Ocular Absorption Modeling and Simulation to Understand the Impact of Formulation Properties on Ophthalmic Bioavailability in Rabbits: a Case Study Using Dexamethasone Suspension. Le Merdy M; Fan J; Bolger MB; Lukacova V; Spires J; Tsakalozou E; Patel V; Xu L; Stewart S; Chockalingam A; Narayanasamy S; Rouse R; Matta M; Babiskin A; Kozak D; Choi S; Zhang L; Lionberger R; Zhao L AAPS J; 2019 May; 21(4):65. PubMed ID: 31111305 [TBL] [Abstract][Full Text] [Related]
7. Intraocular distribution of topically applied hydrophilic and lipophilic substances in rat eyes. Abdul Nasir NA; Agarwal P; Agarwal R; Iezhitsa I; Alyautdin R; Nukolova NN; Chekhonin VP; Mohd Ismail N Drug Deliv; 2016 Oct; 23(8):2765-2771. PubMed ID: 26289215 [TBL] [Abstract][Full Text] [Related]
8. Ocular pharmacokinetics and availability of topically applied baicalein in rabbits. Zhang L; Zhang J; Wang L; Xia H Curr Eye Res; 2009 Apr; 34(4):257-63. PubMed ID: 19373573 [TBL] [Abstract][Full Text] [Related]
9. Topical pharmacokinetics of dexamethasone suspensions in the rabbit eye: Bioavailability comparison. Naageshwaran V; Ranta VP; Toropainen E; Tuomainen M; Gum G; Xie E; Bhoopathy S; Urtti A; Del Amo EM Int J Pharm; 2022 Mar; 615():121515. PubMed ID: 35091006 [TBL] [Abstract][Full Text] [Related]
10. Ocular preparations: the formulation approach. Kaur IP; Kanwar M Drug Dev Ind Pharm; 2002 May; 28(5):473-93. PubMed ID: 12098838 [TBL] [Abstract][Full Text] [Related]
11. Ocular drug metabolism of the bioactivating antioxidant N-acetylcarnosine for vision in ophthalmic prodrug and codrug design and delivery. Babizhayev MA Drug Dev Ind Pharm; 2008 Oct; 34(10):1071-89. PubMed ID: 18777243 [TBL] [Abstract][Full Text] [Related]
12. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. Jiao J Adv Drug Deliv Rev; 2008 Dec; 60(15):1663-73. PubMed ID: 18845195 [TBL] [Abstract][Full Text] [Related]
13. Solid lipid nanoparticles for ocular drug delivery. Seyfoddin A; Shaw J; Al-Kassas R Drug Deliv; 2010; 17(7):467-89. PubMed ID: 20491540 [TBL] [Abstract][Full Text] [Related]
14. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability. Gan L; Han S; Shen J; Zhu J; Zhu C; Zhang X; Gan Y Int J Pharm; 2010 Aug; 396(1-2):179-87. PubMed ID: 20558263 [TBL] [Abstract][Full Text] [Related]
15. Fabrication of a drug delivery system that enhances antifungal drug corneal penetration. Li J; Li Z; Liang Z; Han L; Feng H; He S; Zhang J Drug Deliv; 2018 Nov; 25(1):938-949. PubMed ID: 29658325 [TBL] [Abstract][Full Text] [Related]
16. Biopharmaceutics of Topical Ophthalmic Suspensions: Importance of Viscosity and Particle Size in Ocular Absorption of Indomethacin. Toropainen E; Fraser-Miller SJ; Novakovic D; Del Amo EM; Vellonen KS; Ruponen M; Viitala T; Korhonen O; Auriola S; Hellinen L; Reinisalo M; Tengvall U; Choi S; Absar M; Strachan C; Urtti A Pharmaceutics; 2021 Mar; 13(4):. PubMed ID: 33810564 [TBL] [Abstract][Full Text] [Related]
17. In Situ Gel Formulation for Enhanced Ocular Delivery of Nepafenac. Shelley H; Rodriguez-Galarza RM; Duran SH; Abarca EM; Babu RJ J Pharm Sci; 2018 Dec; 107(12):3089-3097. PubMed ID: 30170009 [TBL] [Abstract][Full Text] [Related]
18. Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye. Loftsson T; Stefánsson E Acta Ophthalmol Scand; 2002 Apr; 80(2):144-50. PubMed ID: 11952479 [TBL] [Abstract][Full Text] [Related]